Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534620 | 0.90 | L3MBTL1 (0.57) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL3290815 | 0.83 | GABBR2 (0.48) | KMT2AHTTTSHRMAPTHPGD | |
| SCHEMBL2517935 | 0.83 | GABBR2 (0.48) | KMT2AHTTTSHRMAPTHPGD | |
| SCHEMBL10071740 | 0.83 | KMT2A (0.57) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL7720266 | 0.82 | TSHR (0.52) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL1775169 | 0.81 | KMT2A (0.46) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL7054346 | 0.81 | L3MBTL1 (0.51) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL7054341 | 0.81 | L3MBTL1 (0.51) | L3MBTL1KMT2ANPSR1POLBHTT | |
| SCHEMBL7624631 | 0.80 | KCNA5 (0.50) | L3MBTL1KMT2APOLBTSHRMEN1 | |
| SCHEMBL4780750 | 0.80 | ALDH1A1 (0.51) | L3MBTL1KMT2ANPSR1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8128727-B2 | Method for collecting metal | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20080261477-A1 | METHOD FOR COLLECTING METAL | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | L3MBTL1 2061/4885KMT2A 3107/4885NPSR1 371/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | L3MBTL1 4657/4885KMT2A 1892/4885NPSR1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.